August 31, 2026 07:09 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
VHP breaks silence on Durga Puja ‘guidelines’: No blanket non-veg ban, clarifies stand on theme pandals amid backlash | No non-veg near pandals, no ‘distorted’ idols: VHP’s Durga Puja guidelines spark Bengal debate | ‘Either they will stay, or we will’: Suvendu Adhikari's warning to Jadavpur students over 'Azadi' slogans | 'Inaccurate reports': Penguin India denies dropping Sonia Gandhi memoir | ‘Clean my shoes’: Greater Noida woman detained after alleged abuse, assault of security guards | 21-year-old model stabbed to death in Delhi; gym trainer arrested after encounter | Abhishek Banerjee, Derek O'Brien, other TMC leaders booked after Camac Street clash with Kolkata Police | Kanpur plane crash: Training aircraft crashes near Ganges, two pilots killed | Big IT boost for Bengal: LTM opens global delivery & AI centre in Kolkata's New Town | 21-year-old Delhi model found stabbed at Delhi home, gym trainer accused of killing her
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.